Neuronetics, Inc. (NASDAQ:STIM) is reporting second quarter financial results on Tuesday 4th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, STIM is expected to report 2Q20 loss of $ 0.51 per share from revenue of $ 8.20 million.
For the full year, analysts anticipate top line of $ 44.37 million, while looking forward to loss of $ 1.87 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 69.00 million ~ $ 71.00 million
Click Here For More Historical Outlooks Of Neuronetics, Inc.
Previous Quarter Performance
Neuronetics, Inc. communicated loss for the first quarter of $ 0.68 per share, from the revenue of $ 11.48 million. The quarterly revenues reduced 9.54 percent compared with the same quarter last year. According to street consensus, STIM was expected to report 1Q20 loss of $ 0.50 per share from revenue of $ 13.01 million. The bottom line results missed street analysts by $ 0.18 or 36 percent, at the same time, top line results fell short of analysts by $ 1.53 million or 11.76 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Neuronetics, Inc.
Stock Performance
According to the previous trading day, closing price of STIM was $ 2.71, representing a 116.80 % increase from the 52 week low of $ 1.25 and a 77.79 % decrease over the 52 week high of $ 12.20.
The company has a market capital of $ 50.76 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”STIM” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Neuronetics, Inc. will be hosting a conference call at 8:30 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neurostar.com
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
